Investigating the effects of peroxisome proliferator activated receptor gamma variations Pro12Ala and C161T on breast cancer


Creative Commons License

Ünal Rıdvanov E., Aslan E. I. , Kurnaz Gömleksiz Ö., Öztürk T., Tüzüner M. B. , Seyhan M. F. , ...More

7th International Congress of Molecular Medicine, İstanbul, Turkey, 5 - 07 September 2019, pp.3-4

  • Publication Type: Conference Paper / Full Text
  • City: İstanbul
  • Country: Turkey
  • Page Numbers: pp.3-4

Abstract

Aims
Breast cancer is one of the most common types of cancer worldwide[1]. Peroxisome proliferating activated receptor gamma (PPAR gamma) is playing a very important role in this cancer type. These factors, which are ligand-bound transcription factors from the nuclear receptor superfamily, have previously been studied in cancer studies, but contradictory results have been found[2].
Methods
In this study, Pro12Ala and C161T variations of PPAR gamma were examined. For this purpose, DNA samples obtained from 95 breast cancer patients and 119 healthy individuals were subjected to Polymerase Chain Reaction(PCR), and Restriction Fragment Length Polymorphism(RFLP) methods and the obtained data were analyzed by SPSS program.
The present work was supported by the Research Fund of Istanbul University. Project No. 24082
Results
When Pro12Ala polymorphism was examined, ProPro genotype and Pro allele were found to be higher in patients (p<0.001). In the C161T polymorphism, minor T allele was more common in patients than in healthy subjects (p<0.001). In logistic regression analysis, it was observed that carrying ProPro genotype of Pro12Ala and T allele of C161T together increased the risk of breast cancer by 7.8 times (p<0.001).
Conclusions
In our study, PPAR gamma Pro12Ala ProPro genotype and C161T T allele were found to be associated with an increased risk of breast cancer. Also, it was observed that the risk of carrying both of the risky alleles was associated with increased risk in breast cancer. In conclusion, we can say that gene variations that alter PPAR gamma activity may affect breast cancer risk.